RXST STOCK UPDATE: RxSight, Inc. (NASDAQ:RXST) is being Sued for Securities Fraud – Contact BFA Law by September 22 Class Action Deadline

Group 1 - A lawsuit has been filed against RxSight, Inc. and certain senior executives for potential violations of federal securities laws [1][2] - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2] - The case is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2] Group 2 - RxSight manufactures and sells light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3] - The company has faced "adoption challenges" and a slowdown in LAL utilization, which was first noted in 2024 [4] Group 3 - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5] - On July 8, 2025, the company further reduced its revenue forecast, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6]